Study Overview

The purpose of this study is to see how long telavancin stays in the body of children aged 1 to 17 years old. Telavancin is a drug approved to treat infections in adults, but has never been given to children before. Information obtained from this study will show how safe one dose of telavancin is in children, and what the blood levels of telavancin are over time in children after one dose (known as pharmacokinetics).

Study Eligibility

Must be 1-17 years of age with an infection.


For more information about this study, contact Lee Howard at 501-364-6990.